Kornitzer Capital Management Has Raised Five9 (FIVN) Position By $2.20 Million; Repros Therapeutics (RPRX) Shorts Down By 47.66%

September 6, 2017 - By Henry Gaston

Kornitzer Capital Management Inc increased Five9 Inc (FIVN) stake by 36.51% reported in 2016Q4 SEC filing. Kornitzer Capital Management Inc acquired 157,094 shares as Five9 Inc (FIVN)’s stock rose 30.16%. The Kornitzer Capital Management Inc holds 587,344 shares with $8.33M value, up from 430,250 last quarter. Five9 Inc now has $1.17B valuation. The stock declined 2.49% or $0.53 reaching $20.92 on the news. About 100,691 shares traded. Five9 Inc (NASDAQ:FIVN) has risen 123.16% since September 6, 2016 and is uptrending. It has outperformed by 106.46% the S&P500.

Repros Therapeutics Incorporated (NASDAQ:RPRX) had a decrease of 47.66% in short interest. RPRX’s SI was 978,200 shares in September as released by FINRA. Its down 47.66% from 1.87 million shares previously. With 984,200 avg volume, 1 days are for Repros Therapeutics Incorporated (NASDAQ:RPRX)’s short sellers to cover RPRX’s short positions. The SI to Repros Therapeutics Incorporated’s float is 3.69%. It is 0.13% or $0 reaching $0.303 per share. It is down 73.82% since September 6, 2016 and is downtrending. It has underperformed by 90.52% the S&P500.

Investors sentiment decreased to 0.22 in Q4 2016. Its down 0.87, from 1.09 in 2016Q3. It fall, as 8 investors sold Repros Therapeutics Inc shares while 8 reduced holdings. 4 funds opened positions while 10 raised stakes. 6.56 million shares or 1.15% more from 6.48 million shares in 2016Q3 were reported. Benjamin F Edwards invested in 2,700 shares. Wells Fargo Co Mn holds 5,400 shares or 0% of its portfolio. California Employees Retirement Sys invested in 0% or 118,000 shares. Tower Research Capital Lc (Trc) has 343 shares for 0% of their portfolio. Creative Planning has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Manufacturers Life Ins The holds 0% or 1,321 shares in its portfolio. Geode Cap Mgmt Limited Liability holds 0% or 133,328 shares. Bankshares Of New York Mellon has invested 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX). Susquehanna Intll Grp Incorporated Limited Liability Partnership accumulated 0% or 71,827 shares. State Bank Of America De, a North Carolina-based fund reported 38,725 shares. Blackrock Institutional Tru Company Na owns 700,608 shares or 0% of their US portfolio. State Street Corporation holds 0% or 13,551 shares. Barclays Public Ltd Co has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 39 shares. Prelude Cap Management Ltd Liability Corporation has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 3,700 shares. Citigroup holds 985 shares.

Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has market cap of $11.14 million. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. It currently has negative earnings. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

Among 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Repros Therapeutics had 5 analyst reports since August 20, 2015 according to SRatingsIntel. The stock of Repros Therapeutics Inc (NASDAQ:RPRX) earned “Buy” rating by Ladenburg Thalmann on Wednesday, November 16. Zacks upgraded it to “Hold” rating and $8.75 target in Thursday, August 20 report. The rating was downgraded by Ladenburg Thalmann on Friday, October 30 to “Neutral”. Brean Capital downgraded the stock to “Hold” rating in Friday, October 30 report. The company was downgraded on Friday, October 30 by Bank of America.

Kornitzer Capital Management Inc decreased Ceb Inc stake by 61,705 shares to 178,970 valued at $10.85 million in 2016Q4. It also reduced Class A stake by 14,733 shares and now owns 53,829 shares. Conocophillips (NYSE:COP) was reduced too.

Among 10 analysts covering Five9 Inc (NASDAQ:FIVN), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Five9 Inc had 19 analyst reports since October 9, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, July 11 by Canaccord Genuity. The rating was maintained by Canaccord Genuity with “Buy” on Friday, August 4. The firm has “Buy” rating given on Monday, May 16 by Needham. Canaccord Genuity maintained the shares of FIVN in report on Thursday, December 3 with “Buy” rating. On Thursday, June 9 the stock rating was initiated by Craig Hallum with “Buy”. As per Thursday, April 14, the company rating was initiated by Roth Capital. The firm has “Underperform” rating given on Tuesday, September 20 by Bank of America. The firm has “Equal-Weight” rating given on Thursday, July 20 by Morgan Stanley. Northland Capital maintained it with “Buy” rating and $2500 target in Wednesday, July 19 report. The rating was maintained by Barclays Capital on Wednesday, January 6 with “Overweight”.